Pfizer: Cheap For A Reason, But I Remain Bullish

JHVEPhoto My thesis After publishing a bullish thesis on Pfizer (NYSE:PFE) on June 5, the stock initially rallied, climbing to over $30 per share by the end of July. This surge seemed to validate the optimistic outlook. Pfizer's initial momentum, unfortunately, didn't last. The stock price dropped sharply following the Q2 earnings report release. This decline was particularly notable given the broader market context. While the overall stock market grew by 3% during this period, Pfizer's stock went again ...